|
Miralles-López J.C., Bravo-Gutierrez F.J., Andújar-Espinosa R., Castilla-Martínez M., Díaz-Chantar C., Ramírez-Hernández M., Cabrejos-Perotti S., Avilés-Inglés M.J., Ibarra-Calabuig I., Reyes-Cotes M.H., Pajarón-Fernández M.J., Bernabéu-Mora R., Alcalde-Rumayor C., Alemany-Francés M.L., Valverde-Molina J., Pérez-Fernández V. Real-life effectiveness of tezepelumab in severe asthma. Allergologia et immunopathologia. 2025. 53:163-173. 10.15586/aei.v53i2.1326
AÑO: 2025; IF: 2.1
|
40088034
|
Alvarez-Gutierrez FJ, Blanco Aparicio M, Casas Maldonado F, Plaza V, Soto Campos G, Gonzalez-Barcala FJ, Almonacid C, Arismendi E, Cabrera C, Cabestre Garcia R, Carretero JA, Castilla Martinez M, Castillo Vizuete JA, Cisneros Serrano C, Diaz de Atauri AG, Diaz Perez D, Domingo Ribas C, Garcia Rivero JL, Lopez Neyra A, Martinez Moragon E, de Mir Messa I, Munoz Gall X, Padilla Galo A, Perpina Tordera M, Perez de Llano L, Sanchez Toril F, Sanz Santiago V, Valverde Molina J. [Consensus document for Severe Asthma. 2025 Update]. Open Respir Arch. 2025 Aug 31;7(4):100486. doi: 10.1016/j.opresp.2025.100486. eCollection 2025 Oct-Dec. Spanish. PubMed PMID: 41049458; PubMed Central PMCID: PMC12495165.
AÑO: 2025
|
|
Miralles-Lopez JC, Cortes Collado JJ, Petryk Petryk Y, Bravo-Gutierrez FJ, Andujar-Espinosa R, Ramirez Hernandez M, Castilla-Martinez M, Diaz-Chantar C, Ibarra-Calabuig I, Valverde-Molina J, Perez-Fernandez V, Group RA. Real-life efficacy of Tezepelumab in patients with failure to other biologic drugs. Eur Ann Allergy Clin Immunol. 2025 Oct 10. doi: 10.23822/EurAnnACI.1764-1489.416. Online ahead of print. No abstract available. PubMed PMID: 41070810.
AÑO: 2025; IF: 2.3
|
|
Alvarez-Gutierrez FJ, Casas-Maldonado F, Valverde-Molina J. News From the Severe Asthma Consensus 2025 Review. Arch Bronconeumol. 2025 Nov 14:S0300-2896(25)00409-0. doi: 10.1016/j.arbres.2025.11.003. Online ahead of print. No abstract available. English, Spanish. PubMed PMID: 41314900.
AÑO: 2025; IF: 9.2
|
|
Gupta A, de Mir Messa I, Valverde-Molina J, Murray CS, Moral L, Torres Borrego J, Pike K, Diaz-Izquierdo A, Martinez-Canavate A, Nagakumar P, Cook J, Gupta L; CASAM Group. Protocol for an open labelled observational study in children & adolescents with severe asthma with an eosinophilic phenotype treated with mepolizumab (CASAM). PLoS One. 2025 Dec 19;20(12):e0335399. doi: 10.1371/journal.pone.0335399. eCollection 2025. PubMed PMID: 41417800; PubMed Central PMCID: PMC12716689.
AÑO: 2025; IF: 2.6
|